Motley Fool Asset Management LLC Purchases 2,135 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Motley Fool Asset Management LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 37,509 shares of the biopharmaceutical company’s stock after acquiring an additional 2,135 shares during the period. Motley Fool Asset Management LLC’s holdings in Gilead Sciences were worth $3,039,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in GILD. OFI Invest Asset Management purchased a new stake in Gilead Sciences during the 3rd quarter valued at approximately $26,000. Tompkins Financial Corp grew its holdings in shares of Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares in the last quarter. Fortitude Family Office LLC bought a new stake in Gilead Sciences in the fourth quarter worth $29,000. Rakuten Securities Inc. bought a new stake in Gilead Sciences in the fourth quarter worth $33,000. Finally, Financial Connections Group Inc. bought a new stake in Gilead Sciences in the fourth quarter worth $40,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Mizuho lowered their price target on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. StockNews.com downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, April 19th. Royal Bank of Canada lowered their price target on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 14th. Truist Financial downgraded Gilead Sciences from a “buy” rating to a “hold” rating and lowered their price target for the stock from $91.00 to $82.00 in a research report on Thursday, February 22nd. Finally, Oppenheimer reissued an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a research note on Friday, April 19th. Ten analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $84.57.

Gilead Sciences Stock Down 2.7 %

NASDAQ:GILD traded down $1.81 during mid-day trading on Thursday, reaching $65.27. The company’s stock had a trading volume of 15,163,484 shares, compared to its average volume of 7,415,576. Gilead Sciences, Inc. has a 1 year low of $65.09 and a 1 year high of $87.86. The stock has a fifty day moving average of $71.40 and a 200-day moving average of $76.32. The firm has a market capitalization of $81.27 billion, a PE ratio of 14.50, a price-to-earnings-growth ratio of 0.96 and a beta of 0.19. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The company had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. During the same period in the prior year, the firm earned $1.37 earnings per share. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. Equities research analysts forecast that Gilead Sciences, Inc. will post 5.24 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were paid a $0.77 dividend. The ex-dividend date was Thursday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 dividend on an annualized basis and a yield of 4.72%. Gilead Sciences’s dividend payout ratio is 68.44%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.